New Triple-Drug combo aims to tackle rare lymphoma

NCT ID NCT03523975

First seen Mar 18, 2026 · Last updated May 14, 2026 · Updated 8 times

Summary

This study is testing whether adding an experimental drug called venetoclax to two standard drugs (lenalidomide and rituximab) is safe and works well for people with untreated mantle cell lymphoma, a rare blood cancer. About 28 adults will take the three drugs together. The goal is to find the best dose and see how many patients achieve complete remission.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Medical center

    RECRUITING

    Duarte, California, 91010, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Ohio State University Comprehensive Cancer Center

    NOT_YET_RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Virginia Cancer Center

    RECRUITING

    Charlottesville, Virginia, 22903, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.